Editas Medicine (LTS:0IFK) 3-Year EBITDA Growth Rate : 1.30% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Editas Medicine 3-Year EBITDA Growth Rate?

Editas Medicine's EBITDA per Share for the three months ended in Dec. 2023 was $-0.28.

During the past 3 years, the average EBITDA Per Share Growth Rate was 1.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Editas Medicine was 8.30% per year. The lowest was -49.00% per year. And the median was -5.00% per year.

Competitive Comparison of Editas Medicine's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Editas Medicine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Editas Medicine's 3-Year EBITDA Growth Rate falls into.

Editas Medicine 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Editas Medicine (LTS:0IFK) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Editas Medicine 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Editas Medicine's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine (LTS:0IFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (LTS:0IFK) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

EDIT:USA 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine (LTS:0IFK) Headlines

No Headlines